Granahan Investment Management Inc. MA lowered its position in Core Laboratories N.V. (NYSE:CLB) by 90.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,276 shares of the oil and gas company’s stock after selling 117,924 shares during the period. Granahan Investment Management Inc. MA’s holdings in Core Laboratories N.V. were worth $1,418,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of CLB. Genesee Valley Trust Co. boosted its stake in shares of Core Laboratories N.V. by 0.3% in the first quarter. Genesee Valley Trust Co. now owns 5,538 shares of the oil and gas company’s stock worth $639,000 after buying an additional 16 shares during the period. Integrated Investment Consultants LLC raised its position in shares of Core Laboratories N.V. by 0.8% in the first quarter. Integrated Investment Consultants LLC now owns 2,330 shares of the oil and gas company’s stock valued at $269,000 after buying an additional 19 shares during the period. Stephens Inc. AR raised its position in shares of Core Laboratories N.V. by 1.0% in the first quarter. Stephens Inc. AR now owns 3,046 shares of the oil and gas company’s stock valued at $352,000 after buying an additional 31 shares during the period. Creative Planning raised its position in shares of Core Laboratories N.V. by 1.9% in the first quarter. Creative Planning now owns 1,730 shares of the oil and gas company’s stock valued at $200,000 after buying an additional 33 shares during the period. Finally, First Bank & Trust raised its position in Core Laboratories N.V. by 2.7% in the first quarter. First Bank & Trust now owns 1,411 shares of the oil and gas company’s stock valued at $163,000 after buying an additional 37 shares during the last quarter.
Shares of Core Laboratories N.V. (NYSE CLB) traded down 0.04% during trading on Wednesday, reaching $104.99. The company’s stock had a trading volume of 307,028 shares. Core Laboratories N.V. has a one year low of $96.30 and a one year high of $127.82. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 69.53 and a beta of 1.60. The firm’s 50-day moving average price is $103.76 and its 200-day moving average price is $112.86.
Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Wednesday, April 19th. The oil and gas company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.03. Core Laboratories N.V. had a net margin of 11.10% and a return on equity of 43.28%. The firm had revenue of $157.81 million during the quarter, compared to the consensus estimate of $150.44 million. During the same quarter in the previous year, the firm posted $0.37 EPS. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities analysts anticipate that Core Laboratories N.V. will post $2.19 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, August 14th. Investors of record on Monday, July 17th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.09%. The ex-dividend date of this dividend is Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is 145.70%.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/granahan-investment-management-inc-ma-cuts-position-in-core-laboratories-clb-updated-updated/1073040.html.
Several research firms have weighed in on CLB. BidaskClub raised Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Zacks Investment Research downgraded Core Laboratories N.V. from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $130.00 price objective (down from $150.00) on shares of Core Laboratories N.V. in a research report on Wednesday, June 21st. Royal Bank Of Canada set a $145.00 price objective on Core Laboratories N.V. and gave the company a “buy” rating in a research report on Saturday, June 17th. Finally, ValuEngine cut Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $122.10.
Core Laboratories N.V. Company Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with our FREE daily email newsletter.